The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...

U.S. National Economic Council Director Kevin Hassett on Thursday dismissed the possibility of China retaliating to tariffs ...

Shares of Amgen Inc. AMGN rallied 1.36% to $309.85 Thursday, on what proved to be an all-around dismal trading session for ...

Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...

New evidence suggests that factors other than the percentage of weight loss should be considered when determining the success ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Amgen (AMGN) concluded the recent trading session at $310.09, signifying a +1.44% move from its prior day's close.

Amgen ( NASDAQ: NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label ...

Amgen (AMGN) announced that the U.S. FDA has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related ...

The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in ...

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and onl ...